NFE2L2 and cancer: These results thus suggest that Keap1/Nrf2 pathway inhibition mediated by K‐563 contributed to cell growth inhibition in human cancer cells harboring Keap1 or Nrf2 mutations, and that this inhibitory effect might be based on the selectivity of K‐563 for the Keap1/Nrf2 pathway.